Nvidia Options Price in $280 Billion Earnings Swing 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Tesla Raises Cybertruck Prices by $5,000 in US 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Ampol Profit Surges as Refining Margins Hit Record Highs 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Add as a preferred source on Google
SAN DIEGO, May 02, 2018 -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will report financial results for the first quarter 2018 as well as provide a corporate update at 4:30 p.m. EDT on May 9, 2018.
The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 3689458. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for otology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Senior Vice President
619.849.5377
[email protected]
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
[email protected]
